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Abstract. Tumor protein 53 mutations adversely affect the 
prognosis of myelodysplastic syndromes (MDS); however, 
few studies have reported on the prognostic significance of the 
expression of p53 protein in MDS. The current study investi-
gated p53 immunoreactivity (p53-IR) in bone marrow biopsies 
(BMBs) obtained at diagnosis from 18 patients (6 females and 
12 males; mean age, 50.5 years) with MDS that underwent 
bone marrow transplantation (BMT) to determine the associa-
tions between clinical and histopathological data and outcome. 
There were 5 refractory cytopenia with multilineage dysplasia 
(RCMD) and 13 refractory anemia with excess blasts, type 2 
(RAEB-2) cases. p53-IR was assessed as the percentage of 
hematopoietic cells exhibiting intense nuclear staining. The 
cut off for positivity was 5% of stained cells. A positive p53-IR 
was detected in 7 patients (38.9%) and was associated with 
age (P=0.005) and pattern of BM fibrosis (P=0.03). A positive 
p53-IR was more frequent in females, in highly cellular BMBs 
and in RAEB-2 cases. Overall survival (OS) was associated 
with patients' age (P=0.01), hemoglobin level (P=0.04), type of 
MDS (P=0.05), degree of BM fibrosis (P=0.006) and number 
of BM blasts (P=0.05). The OS of patients with negative 
p53-IR tended to be longer compared with that of patients with 
positive p53-IR, although this difference was not statistically 
significant (P=0.1). Despite the limitation of the low number 
of cases, the present results indicate that a positive p53-IR at 
diagnosis is associated with clinically more aggressive MDS 
subtypes and adverse histological prognostic factors, such as 
BM fibrosis. Therefore, the evaluation of p53 expression of 
BMBs of patients with MDS may be introduced in the histo-
pathological work-up of the disease. 
Introduction
Myelodysplastic syndromes (MDS) are a group of clonal hema-
tological disorders characterized by ineffective hematopoiesis, 
peripheral cytopenias and an increased risk of development 
of acute myeloid leukemia (1). A number of chromosomal 
abnormalities have been detected in ~50-60% of patients with 
de novo MDS and in ≤80% of patients with therapy‑related 
MDS (2). Among the classical oncogenic abnormalities, those 
involving the tumor protein 53 (TP53) gene have been exten-
sively investigated in MDS. TP53 mutations were detected 
primarily in high-risk and therapy-related MDS, frequently in 
association with complex chromosomal abnormalities (3,4). In 
such diseases, TP53 mutations were revealed to have a nega-
tive prognostic impact (3,5).
The wild-type p53 protein is normally undetectable by 
immunohistochemistry (IHC), due to its short half-life. By 
contrast, the majority of mutated proteins have a prolonged 
half-life, accumulate within the nucleus and can be easily 
detected in formalin-fixed, paraffin-embedded tissues (6). 
Thus, the immunohistochemical detection of p53 protein 
suggests an underlying mutation in the gene (7). It has been 
previously demonstrated that aberrant nuclear expression of 
p53 protein is associated with hemizygous p53 deletion in 
multiple myeloma (8,9) and chronic lymphocytic leukemia (10). 
In MDS, immunohistochemical staining for TP53 protein in 
bone marrow trephine biopsies has revealed a strong correla-
tion with TP53 mutation status (11-13).
A large number of previous studies have reported on the 
strong prognostic significance of the immunohistochemical 
detection of p53 protein in tumor pathology; however, few 
studies have evaluated its prognostic value in MDS (14-16), 
and certain studies primarily focused on low-risk MDS with 
del(5q) (11,17).
In the present study, p53 immunoreactivity (p53-IR) was 
investigated in bone marrow biopsies (BMBs) of patients with 
MDS that underwent bone marrow transplantation (BMT), 
with the aim of determining its association with clinical and 
histopathological data.
Patients and methods
A total of 18 patients that were admitted to the Division of 
Haematology (Città della Salute e della Scienza and University 
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of Turin, Italy) from December 1994 to June 2005, with a 
diagnosis of MDS were retrospectively examined. There 
were 6 females and 12 males; the mean age was 50.5 years 
(range, 32-64). Diagnosis of MDS was performed according 
to the World Health Organization (WHO) criteria (1). In total, 
5 patients had refractory cytopenia with multilineage dysplasia 
(RCMD) and 13 patients had refractory anemia with excess 
blasts, type 2 (RAEB-2). Hemoglobin level, white blood cell 
(WBC) and platelet counts were assessed from peripheral blood 
at diagnosis. All patients underwent allogeneic bone marrow 
transplantation. General informed consent was obtained 
according to the guidelines of the Ethics Committee, Città 
della Salute e della Scienza and University of Turin. Samples 
were numerically identified, maintaining patients' anonymity.
BM morphology and immunohistochemistry. Serial sections 
(3‑µm thick) from Bouin's solution‑fixed, paraffin‑embedded 
BMBs were stained with hematoxylin-eosin, Dominici, Perls 
and reticulin (Fig. 1A) and immunostained with an automated 
stainer device (Leica BOND III, Leica Biosystems, Melbourne 
Pty Ltd, Mount Waverley VIC 3149, Australia) using a poly-
clonal antibody against myeloperoxidase (cat. no. A0398; 
Dako; Agilent Technologies, Inc., Santa Clara, CA, USA; dilu-
tion, 1:1,000), and monoclonal antibodies against glycophorin 
A (clone JC159, #M0819; Dako; Agilent Technologies, 
Inc., Santa Clara, CA, USA; dilution, 1:50), CD61 (clone 
2f2; cat. no. 760-4249; Ventana Medical Systems, Tucson, 
AZ, USA; undiluted), CD34 (Fig. 1B) (clone QBEnd/10; 
cat. no. NCL-L-END; Novocastra; Leica Microsystems, 
Milton Keynes, UK; dilution, 1;50) and p53 (clone DO7, 
#NCL-L-p53-DO7; Novocastra; Leica Microsystems, Milton 
Keynes, UK; dilution, 1:100) at room temperature for 15 min.
Paraffin sections (3‑µm thick) on SuperFrost microscope 
slides were processed with an automated stainer device (Leica 
BOND III, Leica Microsystems) and pretreated for 30 min 
in citrate buffer (pH 6.0; Bond Epitope Retrieval Solution 1, 
Leica Microsystems). The DO-7 antibody was applied at a 
1:100 dilution for 30 min at room temperature and detected 
using a Bond Polymer Refine Detection kit (cat. no. DS9800; 
Leica Microsystems) according to the manufacturer's protocol. 
The percentage of cells with intense (p53++) nuclear staining 
was calculated examining ≥1,000 hematopoietic cells at 
a high magnification (x40) using a standard light micro-
scope. The cut off for positivity (13) was 5% of stained cells 
(Fig. 1C and D).
Statistical analysis. The association between p53 immuno-
reactivity (p53-IR) and clinical or hematological parameters 
was assessed using one-way analysis of variance and the 
Fisher's exact test. Univariate survival analyses were based on 
Kaplan-Meier product-limit estimates of survival distribution, 
and differences between survival curves were tested using the 
log-rank test. Overall survival (OS) was calculated from the 
date of diagnosis to the date of the last observation or death. 
All analyses were performed using SPSS version 17 (SPSS 
Inc., Chicago, IL, USA). P<0.05 was considered to indicate a 
statistically significant difference.
Results
Association between p53‑IR, clinical and hematological 
features and bone marrow histology. Positive p53-IR was 
detected in 7/18 (38.9%) patients. Significant associations 
were detected between p53-IR and patient age (mean age, 
57.3 years for positive p53-IR patients vs. 46.4 years for nega-
tive p53‑IR patients; P=0.005) and the pattern of BM fibrosis, 
in which, of the 8 patients with diffuse fibrosis, 6 (75%) were 
p53-IR-positive compared with 1 (16.7%) of the 6 patients 
with focal fibrosis (P=0.03). A trend toward significance was 
found for sex, (positive p53-IR in 67% of females vs. 25% of 
males; P=0.08), BM cellularity (mean BM cellularity, 81.4% 
for p53-IR-positive patients vs. 64.5% for p53-IR-negative 
patients; P=0.1) and the degree of BM fibrosis (44.4% of 
WHO-MF1 and 60% of WHO-MF2 cases were p53-IR-posi-
tive, whereas no WHO-MF0 cases were positive; P=0.1). No 
association was found for hemoglobin level, white blood cell 
Figure 1. (A) RAEB‑2 exhibiting moderate and diffuse reticulin fibrosis (MF‑2) (bone marrow biopsy; Gomori stain; magnification, x400). (B) RAEB‑2 showing 
numerous CD34 immunopositive blasts arranged in clusters (bone marrow biopsy; CD34 immunoperoxidase staining; magnification, x400). (C) RAEB‑2 in 
which >50% of cells have intensely stained nuclei for p53 (p53‑IR positive case; bone marrow biopsy; p53 immunoperoxidase staining; magnification, x400). 
(D) Refractory cytopenia with multilineage dysplasia. Only one myeloid cell shows an intensely p53 stained nucleus (p53-IR negative case) (bone marrow 
biopsy; p53 immunoperoxidase staining; magnification, x400). RAEB‑2, refractory anemia with excess blasts, type 2; p53‑IR, p53 immunoreactivity.
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(WBC) and platelet counts, percentage of CD34 positive blasts 
and MDS type; however, the rate of positive p53-IR was higher 
in patients with RAEB2 (46.2%) than in those with RCMD 
(20%). The results are summarized in Table I.
Associations between p53‑IR, clinicopathological parameters 
and overall survival. At the time of analysis, 13 mortalities 
(72% of patients) had occurred, and 5 patients (28%) were 
alive (censored). The mean OS for the whole series was 
73 months (median, 18; range, 2‑216). OS was significantly 
associated with patient age: At 5-year follow-up, 55% of 
patients younger <51 years were alive compared to 44% 
of older patients (P=0.01). OS was also associated with 
hemoglobin level (5 year OS was 73% for patients with hemo-
globin >8 g/dl vs. 14% for patients with hemoglobin ≤8 g/dl; 
P=0.04), the type of MDS (5 year OS was 80% for patients 
with RCMD vs. 38% for patients with RAEB-2; P=0.05), the 
degree of BM fibrosis (Fig. 1A) (all patients without fibrosis 
were alive after 5 years vs. 34% of patients with WHO MF1/2; 
P=0.006), the number of BM CD34-positive blasts (Fig. 1B) 
(80% of patients with <5% BM blasts were alive after 5 years 
vs. 38% of those with >5% BM blasts; P=0.05). The median 
survival for patients with a negative p53-IR (Fig. 1D) was 
105 months vs. 8 months for patients with a positive p53-IR 
(Fig. 1C) (P=0.1). No difference in OS was found for sex, 
WBC and platelet counts. The results are summarized in 
Table II.
Discussion
Intense p53 (++) immunoreactivity was detected in 7/18 cases 
(38.8%), in line with the rate of positivity (44%) previously 
reported in RCMD/RAEB2 cases (13) using similar staining 
and scoring procedure. Although previous studies used 1 or 
2% of intensely immunostained nuclei as a cut off for p53 
positivity (11,17), the present study used 5% strongly (++) 
immunopositive nuclei as a cut off, as it has been demonstrated 
that in 55 del(5q) patients, all those with >5% p53++ stained 
cells in BM biopsies carried the TP53 mutation (11).
p53 immunopositivity was associated with BM fibrosis in 
the current study, in which no patients without BM fibrosis 
were p53-IR positive, whereas 50% of those with WHO MF1-2 
were, and 75% of patients with diffuse reticulin fibrosis were 
p53-IR positive, by contrast to only 16% of patients with focal 
fibrosis (P=0.03). Although no significant association was 
detected, p53 positivity was higher in RAEB2 than RCMD, in 
accordance with large studies revealing that TP53 mutations 
were observed mainly in patients with intermediate-2 or high 
Table I. Association between p53-IR and clinical and histopathological bone marrow features.
 P53-IR positive (N=7) P53-IR negative (N=11)
 ----------------------------------------- --------------------------------------------
Variable N Mean ± SD  Mean ± SD P-valuea
Age, years 18 57.3±4.6 46.4±8 <0.01
Hb level, g/dl 18 8.38±1.8 9.06±1.70 0.40
WBC count, x109/l 18 3.421±2.989 4.380±3.130 0.60
Plt count, x109/l 18 88.7±99.1 119.5±81.1 0.50
BM cellularity, % 18 81.4±10.7 64.5±27.3 0.10
BM blasts, % 18 13.1±5.9  11.4±7.7   0.60
Variable Ν N (%) N (%) P‑valueb
Sex    
   Male 12 3 (25) 9 (75) 
   Female   6 4 (66.7) 2 (33.3) 0.08
MDS type    
   RCMD   5 1 (20) 4 (80) 
   RAEB-2 13 6 (46.2) 7 (53.8) 0.30
BM fibrosis WHO grade    
   MF-0   4 0 (0) 4 (100) 
   MF-1   9 4 (44.4) 5 (55.6) 0.10
   MF-2   5 3 (60) 2 (40) 
BM fibrosis pattern    
   Focal   6 1 (16.7) 5 (83.3) 
   Diffuse   8 6 (75) 2 (25) 0.03 
aOne-way analysis of variance; bFisher's exact test. p53-IR, p53 immunoreactivity; WBC, white blood cell; Plt, platelet; BM, bone marrow; 
RCDM, refractory cytopenia with multilineage dysplasia; RAEB, refractory anemia with excess blasts; SD, standard deviation; Hb, hemoglobin; 
MDS, myelodysplastic syndromes; WHO, World Health Organization.
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risk MDS (5). Therefore, with the limitation due to the number 
of cases, the current results indicate that a positive p53-IR at 
diagnosis is associated with adverse histological prognostic 
factors, such as BM fibrosis, and with clinically more aggres-
sive MDS subtypes.
In addition, OS was associated with fibrosis in the present 
study; all patients without evidence of fibrosis in BM biopsy 
were alive at the 5-year follow-up, whereas only 34% of those 
with WHO MF‑1/2 disease were (P=0.006). This finding is 
in agreement with large studies demonstrating the clinical 
relevance of bone marrow fibrosis in primary myelodysplastic 
syndromes (18,19). OS was also associated with the type of 
MDS: 80% of patients with RCMD were alive at the 5-year 
follow-up, whereas only 38% of those with RAEB2 were 
(P=0.05).
Notably, in the present series, a positive p53-IR tended to be 
associated with a shorter OS: The median survival for patients 
with negative p53-IR was 105 months but only 8 months for 
those with positive p53-IR (P=0.1). This result is concordant 
with studies revealing the strong prognostic value of p53 
mutations in MDS (3,5,12,20). Mutations in TP53, enhancer 
of zeste homolog 2, ETS variant 6, runt-related transcrip-
tion factor 1 and additional sex combs like 1 transcriptional 
regulator proteins were found to be predictors of poor overall 
survival in patients with MDS; however, only mutations in the 
TP53 gene have been clearly associated with poor prognostic 
Table II. Correlation between clinical and histopathological bone marrow features and p53-IR with overall survival.
  Median overall 1-year overall  5-year overall  
Variable N survival, months survival rate, % survival rate, % P-valuea
Whole series 18 18 61   49 
Sex     
  Male 12 75 67   58 
  Female   6 8.2 50   33 0.60
Age, years     
  ≤51   9 108 66   55 
  >51   9 13 55   44 0.01
WBCs, x109/l     
  ≤1.8   5 12 60   40 
  >1.8 11 9 55   44 0.70
Hb level, g/dl     
  ≤8  7 8 42   14 
  >8 11 105 73   73 0.04
Plt count, x109/l     
  ≤100 10 75 70   60 
  >100   8 9 50   37 0.80
MDS type     
  RCMD   5 105 100   80 
  RAEB-2 13 12 46   38 0.05
BM fibrosis WHO grade     
  MF-0   4 n.a. 100 100 
  MF-1/2 14 12 57   34 <0.01
BM fibrosis pattern     
  Focal   6 18 67   50 
  Diffuse   8 8.2 37.5   25 0.20
BM CD34 positive blasts     
  ≤5   5 105 100   80 
  >5 13 12 46   38 0.05
P53-IR     
  Negative 11 105 73   55 
  Positive   7 8 57   43 0.10 
aLog-rank test. WBC, white blood cell; Plt, platelet; BM, bone marrow; RCDM, refractory cytopenia with multilineage dysplasia; RAEB, 
refractory anemia with excess blasts; p53-IR, p53 immunoreactivity; Hb, hemoglobin; MDS, myelodysplastic syndromes; WHO, World Health 
Organization; n.a., not applicable.
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markers, and have been reported to independently predict 
survival, primarily in patients with intermediate-2 or high 
risk MDS (5). A large single institution study on 318 patients 
with MDS revealed that TP53 mutations were the strongest 
predictor of outcome in a multivariate model (12).
The present results emphasize the prognostic value 
of the immunohistochemical detection of p53 protein in 
MDS (11,14‑17). The finding is particularly relevant, when 
considering the small number of cases and the type of therapy 
of the present series. All patients underwent allogeneic BM 
transplantation, by contrast to the previously reported series, 
which were primarily concerning patients with low- or inter-
mediate risk del(5q) MDS treated with lenalidomide.
Immunohistochemistry is a practical and convenient 
method to detect p53 protein overexpression in tumor cells (6). 
An association has been reported between intense p53 nuclear 
staining and TP53 mutation in MDS (11,13,17); furthermore, 
patients without TP53 mutations did not exhibit intense p53 
protein staining, conferring a good negative predictive value 
for IHC (12). Therefore, the acceptable sensitivity of p53 immu-
nostaining in predicting for TP53 mutations is encouraging, 
and the methodology is routine in diagnostic laboratories.
In conclusion, our findings suggest that the evaluation of 
p53-IR on BMBs of patients with MDS may be introduced in 
the histopathological work-up of the disease.
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